SCHEMBL4893713

SCHEMBL4893713

O=Cc1c2ccccc2cc2cc3ccccc3cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.50
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 2/20 0.43
HIF1A Q16665 1/20 0.43
CYP1B1 Q16678 1/20 0.43
MAPT P10636 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2C9 P11712 1/20 0.42
KDM4E B2RXH2 2/20 0.41
KMT2A Q03164 2/20 0.41
PADI4 Q9UM07 1/20 0.41
MEN1 O00255 1/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 1/20 0.41
AMY1A P0DUB6 1/20 0.41
GAA P10253 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342278 0.91 ERN1 (0.57) ERN1ALDH1A1HSD17B10HIF1ACYP1B1
SCHEMBL29388184 0.91 ERN1 (0.57) ERN1ALDH1A1HSD17B10HIF1ACYP1B1
SCHEMBL10348702 0.89 ERN1 (0.55) ERN1ALDH1A1HSD17B10HIF1ACYP1B1
Methyl Alcohol SCHEMBL27670101 0.85 ERN1 (0.57) ERN1ALDH1A1HSD17B10MAPTCYP1A2
SCHEMBL11483755 0.85 ERN1 (0.50) ERN1ALDH1A1HSD17B10HIF1ACYP1B1
SCHEMBL9883837 0.84 ERN1 (0.48) ERN1ALDH1A1HSD17B10HIF1ACYP1B1
SCHEMBL31317593 0.83 ERN1 (0.43) ERN1ALDH1A1HSD17B10MAPTCYP1A2
SCHEMBL28218594 0.82 KIF11 (0.47) ERN1ALDH1A1HSD17B10MAPTCYP1A2
SCHEMBL8601328 0.81 ERN1 (0.49) ERN1ALDH1A1HSD17B10HIF1ACYP1B1
SCHEMBL5748403 0.81 ALDH1A1 (0.48) ERN1ALDH1A1HSD17B10HIF1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4728836-A1 PEROVSKITE MATERIAL AND USES THEREOF Victoria Link Limited (NZ) 2026-04-22 EP disclosed
US-20250011264-A1 CYCLIC COMPOUND AND METHOD FOR PRODUCING CYCLIC COMPOUND SUMITOMO BAKELITE CO., LTD. (JP) 2025-01-09 US disclosed
WO-2024258297-A1 PEROVSKITE MATERIAL AND USES THEREOF VICTORIA LINK LIMITED (NZ) 2024-12-19 WO disclosed
EP-4434960-A1 CYCLIC COMPOUND AND METHOD FOR PRODUCING CYCLIC COMPOUND Sumitomo Bakelite Co., Ltd. (JP) 2024-09-25 EP disclosed
CN-118265685-A Cyclic compound and method for producing cyclic compound 住友电木株式会社 2024-06-28 CN disclosed
WO-2023090298-A1 CYCLIC COMPOUND AND METHOD FOR PRODUCING CYCLIC COMPOUND 住友ベークライト株式会社 2023-05-25 WO disclosed
CN-113412261-A Benzimidazole compounds, preparation method and use thereof 四川科伦博泰生物医药股份有限公司 2021-09-17 CN disclosed
US-20080044149-A1 Polymerizable Composition TOYO INK MFG. CO., LTD. (JP) 2008-02-21 US disclosed
EP-1816152-A1 POLYMERIZABLE COMPOSITION TOYO INK MFG. CO., LTD. (JP) 2007-08-08 EP disclosed
EP-0182609-B1 POLYCYCLIC BIOCIDAL COMPOUNDS, THEIR SYNTHESIS, FORMULATIONS CONTAINING THEM THE WELLCOME FOUNDATION LIMITED (GB) 1990-05-09 EP disclosed
US-4827034-A ANTITUMOR BURROUGHS WELLCOME CO. (US) 1989-05-02 US disclosed
US-4818443-A ANTITUMOR AGENTS BURROUGHS WELLCOME CO. (US) 1989-04-04 US disclosed
US-4814502-A ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS BURROUGHS WELLCOME CO. (US) 1989-03-21 US disclosed
US-4810823-A ANTITUMOR AGENTS BURROUGHS WELLCOME CO. (US) 1989-03-07 US disclosed
US-4808753-A ANTITUMOR AGENTS BURROUGHS WELLCOME CO. (US) 1989-02-28 US disclosed
US-4791233-A ANTITUMOR AGENTS BURROUGHS WELLCOME CO. (US) 1988-12-13 US disclosed
US-4791231-A ANTITUMOR AGENTS BURROUGHS WELLCOME CO. (US) 1988-12-13 US disclosed
US-4791232-A ANTITUMOR AGENTS BURROUGHS WELLCOME CO. (US) 1988-12-13 US disclosed
EP-0182609-A2 Polycyclic biocidal compounds, their synthesis, formulations containing them THE WELLCOME FOUNDATION LIMITED (GB) 1986-05-28 EP disclosed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011264-A1 CYCLIC COMPOUND AND METHOD FOR PRODUCING CYCLIC COMPOUND CA1, ASIC1, CA7 ERN1 1956/4885ALDH1A1 1024/4885HSD17B10 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.